Cargando…

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study

Alemtuzumab (anti-CD52 antibody) is frequently prescribed to children with nonmalignant diseases undergoing allogeneic hematopoietic stem cell transplantation (HSCT) to prevent graft failure (GF) and acute graft-versus-host disease (aGVHD). The aim of this multicenter study was the characterization...

Descripción completa

Detalles Bibliográficos
Autores principales:	Achini-Gutzwiller, Federica R., Schilham, Marco W., von Asmuth, Erik G. J., Jansen-Hoogendijk, Anja M., Jol-van der Zijde, Cornelia M., van Tol, Maarten J. D., Bredius, Robbert G. M., Güngör, Tayfun, Lankester, Arjan C., Moes, Dirk Jan A. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440472/ https://www.ncbi.nlm.nih.gov/pubmed/37285798 http://dx.doi.org/10.1182/bloodadvances.2022009051

Ejemplares similares

Development and Validation of an Efficient and Highly Sensitive Enzyme-Linked Immunosorbent Assay for Alemtuzumab Quantification in Human Serum and Plasma
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients
por: Bank, Jonna R., et al.
Publicado: (2016)

Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome
por: Admiraal, Rick, et al.
Publicado: (2019)

Late Endocrine Effects After HSCT in Children With Nonmalignant Diseases; A Single Center Cohort Analysis
por: de Kloet, Liselotte C, et al.
Publicado: (2021)

Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
por: Oostenbrink, Lisa V. E., et al.
Publicado: (2019)

ALEMTUZUMAB FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION
por: Girgis, Reda, et al.
Publicado: (2020)

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT
por: Geerlinks, Ashley V., et al.
Publicado: (2023)

A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants
por: Jardine, Laura, et al.
Publicado: (2015)

Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome
por: Counsilman, Clare E., et al.
Publicado: (2015)

Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness
por: Bouvy, Anne P., et al.
Publicado: (2016)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022)

Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell Defect
por: Ott de Bruin, Lisa M., et al.
Publicado: (2023)

Artic area : indigenous period
por: Collins, Henry B.
Publicado: (1954)

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
por: Häußler, Vivien, et al.
Publicado: (2021)

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
por: Burns, D M, et al.
Publicado: (2016)

Killer strangelets: an ARTIC6 adventure
por: Furlong, C T
Publicado: (2010)

Simultaneous Islet and Kidney Transplantation in Seven Patients With Type 1 Diabetes and End-Stage Renal Disease Using a Glucocorticoid-Free Immunosuppressive Regimen With Alemtuzumab Induction
por: Tan, Jianming, et al.
Publicado: (2008)

Clinical Characteristics and Outcomes of COVID-19 in HSCT Recipients
por: Machado, Clarisse MARTINS, et al.
Publicado: (2020)

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders
por: Merli, Pietro, et al.
Publicado: (2022)

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
por: Versluijs, A. Birgitta, et al.
Publicado: (2022)

Modeling Long-Term Erythropoietic Recovery After Allogeneic Stem Cell Transplants in Pediatric Patients
por: von Asmuth, Erik G. J., et al.
Publicado: (2020)

Risk and promise: an 11-year, single-center retrospective study of severe acute GVHD in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases
por: Zaidman, Irina, et al.
Publicado: (2023)

Nonmalignant leukocyte disorders
por: Marionneaux, Steven
Publicado: (2020)

Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?
por: van der Stoep, M. Y. Eileen C., et al.
Publicado: (2022)

The natural course of pregnancies in women with primary atypical haemolytic uraemic syndrome and asymptomatic relatives
por: Timmermans, Sjoerd A. M. E. G., et al.
Publicado: (2020)

Controlled infrared heating of an artic meadow: challenge in the vegetation establishment stage
por: Moni, Christophe, et al.
Publicado: (2019)

An unusual presentation of a patient with severe hypogammaglobulinemia
por: Hoffman, Thijs W., et al.
Publicado: (2018)

Circulating microbial cell–free DNA is increased during neutropenia after hematopoietic stem cell transplantation
por: Blair, Lily M., et al.
Publicado: (2023)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Effect of sirolimus on carotid atherosclerosis in kidney transplant recipients: data derived from a prospective randomized controlled trial
por: Silva, Andre L, et al.
Publicado: (2018)

Exploring the long‐term psychosocial impact of paediatric haematopoietic stem cell transplantation for nonmalignant diseases
por: Bense, Joëll E., et al.
Publicado: (2022)

Keeping the lights on: Telehealth, testing, and 6-month outcomes for orthotopic liver transplantation during the COVID-19 pandemic
por: Delman, Aaron M., et al.
Publicado: (2021)

Looking for the needle in the kidney transplantation haystack
por: Cruzado, Josep M., et al.
Publicado: (2017)

Emergence of human CMV-induced NKG2C(+) NK cells is associated with CD8(+) T-cell recovery after allogeneic HCT
por: van der Ploeg, Kattria, et al.
Publicado: (2023)

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
por: Shouval, Roni, et al.
Publicado: (2022)

The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation
por: Xipell, Marc, et al.
Publicado: (2018)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

PROLONGED COLONIZATION AND COISOLATION OF SARS-COV-2 IN UNVACCINATED RECIPIENTS OF LUNG TRANSPLANTS
por: RAZIA, DEEPIKA, et al.
Publicado: (2022)

Genetic variants associated with inflammatory bowel disease and gut graft-versus-host disease
por: Martin, Paul J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kc3sqoc4m6br83i7jmk9du8rk0